This content is from: Patents

EPO revokes Broad Institute’s CRISPR patent

The EPO has denied the Broad Institute of MIT and Harvard’s reliance on its US priority provisional application in revoking a CRISPR patent. The institute has already said it will appeal

To access our in-house intelligence please request a trial here.

Read this article – and more – for a one-week period.

REQUEST ACCESS

Are you already an Managing IP subscriber? Login here

Related

Instant access to all of our content. Membership Options | One Week Trial